RxSight Forecasts $140M to $160M Revenue for 2026 with Alcon Partnership Adding $30M to $40M
RxSight (NASDAQ:RXST) anticipates revenue of between $140 million and $160 million in 2026, driven by a collaboration with Alcon that is expected to contribute an additional $30 million to $40 million. The company highlighted its development of proprietary hybrid IOL materials for next-generation light adjustable lenses.
Topics: IOL technology R&D developments RxSight